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Abstract
Background: High mammographic density (MD) is a strong risk factor for breast cancer. However, it is unclear
whether high MD is an intermediate phenotype or whether breast cancer risk factors influence breast cancer risk
and MD independently.
Methods: Our study population included 1290 invasive breast cancer cases and 3422 controls from the Nurses’
Health Studies. We estimated the percent of the total association between the risk factor and breast cancer that
was mediated by MD.
Results: In both pre- and postmenopausal women, the association between history of biopsy-confirmed benign
breast disease and risk was partially mediated by percent MD (percent mediated (PM) = 17 %, p < 0.01 and
PM = 33 %, p = 0.04, respectively). In premenopausal women, the associations between early life body size
(adolescent somatotype and BMI at age 18) and breast cancer risk were substantially mediated by percent
MD (PM = 73 %, p = 0.05 and PM = 82 %, p = 0.04, respectively). In postmenopausal women, the proportion
of the associations of childhood somatotype and adolescent somatotype that were mediated by percent MD
were lower (PM = 26 %, p = 0.01 for both measures). Hormone therapy use at mammogram was significantly
mediated by percent MD in postmenopausal women (PM = 22 %, p < 0.01). Associations with other risk factors, such
as age at menarche or family history of breast cancer, were not mediated by percent MD.
Conclusions: Percent MD partially mediated some of the associations between risk factors and breast cancer, though
the magnitude varied by risk factor and menopausal status. These findings suggest that high MD may be an
intermediate in some biological pathways for breast cancer development.
Background
Mammographic density (MD), or the radiographic appear-
ance of the breast on a mammogram, is a strong risk
factor for breast cancer [1]. Dense breast tissue appears
light on a mammogram and is comprised of epithelial and
stromal tissue whereas non-dense tissue, comprised of fat,
appears dark. Women with over 75 % dense tissue have
four to six times the risk of breast cancer compared to
those with very little to no dense tissue [2]. Further, a
number of reproductive and lifestyle risk factors for breast
cancer have been consistently associated with MD [3–8].
Since MD is associated with both lifestyle and repro-
ductive risk factors and with risk of breast cancer, it has
been hypothesized that MD may be an intermediate
marker of breast cancer risk [9]. As a result, percent
MD has been proposed as a potential surrogate marker
for breast cancer risk in intervention trials [8]. However, it
is unknown the extent to which reproductive and lifestyle
factors influence breast cancer risk through their effects
on MD and the extent to which they influence risk though
other pathways,. While some prior studies have examined
whether MD mediates the associations with breast cancer
risk for some risk factors, such as body size and hormone
therapy use, most studies have not attempted to quantify
the extent to which the associations are mediated by MD
[10, 11]. For example, in a prior analysis in the Nurses’
Health Study (NHS) and NHSII, we observed that the
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associations between early life body size (e.g., body mass
index [BMI] at age 18) and breast cancer risk were attenu-
ated after adjustment for percent MD, suggesting that MD
at least partially mediated the associations [10]. However,
we did not estimate the extent to which MD mediated the
associations nor did we examine other established or
probable breast cancer risk factors, such as family history
of breast cancer or reproductive factors [10]. Quantifying
the extent to which MD mediates the associations with
established risk factors would provide insight into breast
cancer etiology, including the role of MD in breast cancer
risk. Therefore, the purpose of this analysis was to quan-
tify the extent to which the associations between estab-
lished lifestyle and reproductive breast cancer risk factors
and breast cancer risk are mediated by MD in a large




In 1976, 121,700 female registered nurses aged 30 to 55
from 11 US states completed an initial questionnaire
forming the NHS cohort. The NHSII began in 1989
when 116,430 female registered nurses, aged 25 to 42,
from 14 US states completed a baseline questionnaire.
Both cohorts are followed by biennially mailed question-
naires to collect information on exposures and covari-
ates as well as incident diseases. In 1989–1990, we
obtained blood samples from 32,826 NHS participants,
ages 43 to 70. From 1996 to 1999, 29,611 NHSII mem-
bers, aged 32 to 45 years, provided blood samples. Our
mammogram collection was conducted within the case-
control studies of breast cancer nested in the NHS/
NHSII blood subcohorts, which have been described
previously [12–14]. Briefly, cases were identified on
biennial questionnaires or through death records. These
participants or their next of kin were asked for permis-
sion to obtain their medical records, which were
reviewed by study investigators. As we confirm 99 % of
reported cases of breast cancer for whom we are able to
obtain medical records, all diagnoses of breast cancer
confirmed by the participant or medical records are in-
cluded as cases in the nested case-control studies. One
or two controls were matched to breast cancer cases on
age, menopausal status at blood draw and diagnosis,
current hormone therapy (HT) use, month, time of day,
fasting status at time of blood collection, and luteal day
(NHSII timed samples only). Mammograms conducted
as close as possible to the date of blood draw were
collected for cases and matched controls diagnosed
after blood collection, but before June 1, 2004 (NHS) or
June 1, 2007 (NHSII). Further, we collected additional
mammograms conducted around 1997 from NHSII
breast cancer cases and controls who participated in
the NHSII cheek cell collection. In total, mammograms
were collected from 2062 breast cancer cases and 4196
matched controls. We further excluded women with
missing data on putative MD and breast cancer risk
factors, specifically menopausal status (n = 385), current
body mass index (BMI) (n = 112), BMI at age 18 (n = 184),
parity (n = 45), age at first birth (N = 4), age at menarche
(n = 23), adolescent somatotype (n = 173), and hormone
therapy (HT) use (n = 194, postmenopausal only). Next,
we excluded women with outlying values based on the
generalized extreme studentized deviate many-outlier
detection approach [15] for the following variables:
BMI (n = 16), BMI at age 18 (n = 18), age at first birth
(n = 8), and age at menarche (n = 2). The study was
approved by the Committee on the Use of Human
Subjects in Research at the Brigham and Women’s
Hospital.
Mammographic density
A Lumysis 85 laser film scanner (Lumisys, Sunnyvale,
CA, USA) was used to digitize the craniocaudal views of
both breasts for all mammograms in the NHS and for
the first two batches of mammograms in the NHSII. The
third batch of mammograms in the NHSII was scanned
using a VIDAR CAD PRO Advantage scanner (VIDAR
Systems Corporation; Herndon, VA, USA) using com-
parable resolution of 150 dots per inch and 12 bit depth.
We measured absolute dense area, absolute non-dense
area (the total area minus the dense area), and percent
MD (the dense area divided by the total area) using the
Cumulus software for computer-assisted thresholding
(Canto Software, San Francisco, CA, USA). Next, we
averaged the density parameters of both breasts. To
assess the potential variability in percent MD by scanner,
we conducted a pilot study of 50 mammograms. These
mammograms were scanned using both the Lumysis 85
laser scanner and the VIDAR CAD PRO Advantage
scanner; percent MD was measured by the same observer
using Cumulus. The correlation between percent density
as measured by the two scanners was 0.88. Two observers
read the mammograms from NHS participants in two
batches. In NHSII, a single observer read the mammo-
grams in three batches (batches 1 and 2 were read 3 years
apart, batches 2 and 3 were read 3 years apart). A small
number of mammograms (N = 50) were included in all
three NHSII batches. While there was high reproducibility
within each batch, there was evidence of between-batch
variability in the NHSII. Therefore, for the overall NHSII
breast cancer case-control mammography dataset, we
used multivariable linear regression models to estimate
the effect of batch on density measurements, controlling
for age, menopausal status, BMI, and case-control status
[16, 17]. We then adjusted density measurements in the
second and third NHSII batches by adding the coefficient
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for each mammogram batch to the raw value to estimate
the measurements that would have been obtained if the
mammogram had been included in the first batch. For all
batches, readers were blinded to case-control status.
Selected breast cancer risk factors
NHS/NHSII participants reported their height and age at
menarche on the baseline questionnaires. Personal history
of benign breast disease (BBD), including whether it was
confirmed by biopsy, and weight were queried on the
baseline and all biennial questionnaires. Weight at age
18 was asked in 1980 (NHS) and in 1989 (NHSII).
Current BMI and BMI at age 18 were calculated as
weight(kg)/height(m)2. In 1988 (NHS) and 1989 (NHSII),
participants were asked to report their body size at ages 5,
10, and 20 using a 9-level figure with a value of 1 being
the leanest figure and 9 being the heaviest figure [10].
Childhood somatotype was calculated as the average of
the somatotypes at ages 5 and 10; adolescent somatotype
was calculated as the average of somatotypes at ages 10
and 20. Participants reported whether they had a first-
degree relative (mother or sister) with a diagnosis of breast
cancer at baseline, in 1982 (NHS), and then every 4 years
beginning in 1988 (NHS) or 1997 (NHSII). In the NHS,
parity and age at first birth were queried on the baseline
questionnaire as well as biennial questionnaires until 1984
and again in 1996 in order to update the data on each par-
ticipant’s lifetime pregnancy history. In the NHSII, parity
and age at first birth were asked on the baseline ques-
tionnaire and respondents reported parity, including
year of each pregnancy, on each subsequent biennial
questionnaire. Birth index (a measure which incorpo-
rates the number of births, age at each birth, and time
since each birth) was calculated as the sum of the total
years from each birth to a woman’s age at mammogram
(or age at menopause if postmenopausal) with nulliparous
women receiving a value of 0 [18]. Breastfeeding history
was asked in 1986 in the NHS and in 1993 and 1997 in
the NHSII. In the NHS, alcohol intake was first asked in
1980 and subsequently in 1984, 1986, and every 4 years
afterwards. In the NHSII, alcohol intake was asked at
baseline, in 1991, and every 4 years afterwards. In the
NHS and NHSII, women were asked about their hormone
therapy use on the baseline and biennial questionnaires.
For all variables included on multiple biannual question-
naires, we used information from the most recent ques-
tionnaire prior to the date of the mammogram.
Statistical analysis
For all analyses, percent MD, dense area, and non-dense
area were square-root transformed to improve normality.
We used linear regression to estimate the differences in
percent MD, dense area, and non-dense area by repro-
ductive and lifestyle risk factors among the controls. To
assess the extent to which the associations between each
of the selected exposures and breast cancer risk are medi-
ated by MD, we used the method for mediation analysis
outlined by Lin et al. implemented using the SAS macro
developed by Spiegelman and colleagues at the Harvard
T.H. Chan School of Public Health [19]. Briefly, this
method uses data augmentation and logistic regression to
compare a model unadjusted for the hypothesized me-
diator to a model adjusted for the hypothesized medi-
ator. Additional information on this method and the
macro can be found at: http://www.hsph.harvard.edu/
donna-spiegelman/software/mediate/. Using this macro,
we estimated the odds ratio (OR) and 95 % confidence
interval (CI) for (a) the association between the selected
exposure and breast cancer risk not adjusted for MD
(i.e., the total association between the exposure and
breast cancer risk) and (b) the association between the
selected exposure and breast cancer risk adjusted for MD
(i.e., the association between the exposure and breast can-
cer risk not through MD). We also estimated the percent of
the total association (on the log odds scale) between the ex-
posure and breast cancer risk that was mediated by MD
using the following equation: 1-(lnORadjusted/lnORunadjusted).
Our primary analysis examined percent MD as a potential
mediator since percent MD is a stronger predictor of subse-
quent breast cancer risk than dense or non-dense area [20].
However, as both dense area and non-dense area have
been independently associated with breast cancer risk
in the NHS/NHSII, we also examined mediation of the
associations by these measures in secondary analyses
[20]. Further, in secondary analyses, we estimated the
percent mediated by percent MD for each of the se-
lected exposures using an alternative method outlined
by VanderWeele and Vansteelandt [21], which, in contrast
to the Lin method, also models interaction between the
exposure and the mediator. Using this method, we calcu-
lated ORs and 95 % CIs for (a) the natural direct effect
(NDE) (i.e., the effect of the exposure on breast cancer risk
not through percent MD if percent MD was fixed at
the level that it would be if the exposure was set to the
referent category), (b) the natural indirect effect (NIE)
(i.e., the effect of the exposure on breast cancer risk
through percent MD), and (c) the total association be-
tween the exposure and breast cancer risk. In the presence
of interaction between the exposure and percent MD, the
NDE will vary depending on the referent category of the
exposure (since percent MD is fixed at the level that it
would be if the exposure was set to the referent category).
Therefore, for all exposures we present the mediation ana-
lysis for both contrasts (e.g., for family history of breast
cancer compared to no family history of breast cancer as
well as for no family history of breast cancer compared to
family history of breast cancer). In the absence of inter-
action between the exposure and percent MD, the ORNDE
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calculated using the VanderWeele and Vansteelandt
method will not vary by the referent category and will ap-
proximate the ORadjusted calculated using the Lin method.
For the VanderWeele and Vansteelandt method, we also
computed the percent of the total association (on the log
odds scale) that was mediated by MD using the formula
1-(lnORNDE/lnORtotal). We further used sensitivity ana-
lyses to assess how robust evidence for mediation was to
potential unmeasured common causes of MD and breast
cancer risk [9, 22]. Lastly, we evaluated whether there was
statistically significant interaction between each exposure
and percent MD by including an interaction term between
the continuous exposure and continuous percent MD and
using the Wald test to assess the significance. As we did
not observe significant interaction with percent MD for
most of the exposures, the Lin method is presented as the
primary analysis.
Exposure variables were modeled continuously ex-
cept for the following binary variables: history of BBD,
nulliparity, family history of breast cancer, past HT
use (vs never), and current HT use (vs never). Total
months breastfeeding was categorized as: <1, 1–3, 4–6,
7–11, 12–17, 18–23, 24–35, and 36+. We assigned women
the value of the midpoint of their category (or 36 for the
highest category) and modeled the category medians con-
tinuously. All models were adjusted for matching factors,
specifically age (continuous), time of blood collection
(12 am–5:59 am, 6:00 am–7:59 am, 8:00 am–11:59 pm),
cohort/batch (NHS batch 1, NHS batch 2, NHSII), fasting
status (no, yes), and HT use (never, past, current; post-
menopausal only). Models were also adjusted for potential
confounders of the association between the exposures
and breast cancer risk, potential confounders of the as-
sociation between the exposures and MD, and poten-
tial confounders of the association between MD and
breast cancer risk. These covariates were current BMI
(continuous), BMI at age 18 (continuous), adolescent
somatotype (continuous), history of BBD (no, yes), nul-
liparity (no, yes), parity (continuous), age at first birth
(continuous), and age at menarche (continuous). In
our primary analysis, early life somatotypes and BMI at
age 18 were not adjusted for adolescent somatotype,
BMI at age 18, or current BMI as these variables are
likely on the causal pathway. However, we adjusted
early life somatotypes and BMI at age 18 by current
BMI in sensitivity analyses. Further, weight change
since age 18 was not adjusted for current BMI. All con-
tinuous variables, including MD measures, were centered
at the median. As the associations between some expo-
sures and breast cancer risk vary by menopausal status
and percent MD is lower in postmenopausal women com-
pared to premenopausal women, all analyses were con-
ducted separately in pre- and postmenopausal women
(menopausal status was defined at the time of the
mammogram). Analyses were conducted using SAS ver-
sion 9.4 (SAS Institute, Cary, NC, USA) and results
were considered statistically significant if p ≤ 0.05.
Results
Table 1 presents participant characteristics at the NHS/
NHSII questionnaire cycle prior to the date of the mam-
mogram by case-control and menopausal status. Partici-
pant characteristics among the controls by quartile of
percent MD and menopausal status are presented in
Additional file 1: Table S1. Further, the associations
between each of the exposures and MD measures among
the controls, adjusting for potential confounders, are
presented in Additional file 2: Table S2. The average time
between mammogram and breast cancer diagnosis was
4.7 years (standard deviation [SD] = 3.4) in women pre-
menopausal at the time of the mammogram and 4.3 years
(SD = 3.5) in postmenopausal women. Among cases who
were premenopausal at mammogram, the mean age at
diagnosis was 50.9; while the mean age at diagnosis among
cases who were postmenopausal at mammogram was
64.4. Of the three measures, percent MD was most
strongly associated with breast cancer risk, adjusting for
age and potential confounders in pre- and postmeno-
pausal women (OR per standard deviation increase = 1.51,
95 % CI: 1.33, 1.71 and OR per standard deviation
increase = 1.34, 95 % CI: 1.21, 1.50; respectively). In both
pre- and postmenopausal women, dense area was posi-
tively associated with breast cancer risk (OR per standard
deviation increase = 1.48, 95 % CI: 1.32, 1.65 and OR per
standard deviation increase = 1.26, 95 % CI 1.13, 1.41;
respectively) whereas non-dense area was inversely associ-
ated with risk (OR per standard deviation increase = 0.80,
95 % CI: 0.69, 0.93 and OR per standard deviation
increase = 0.81, 95 % CI: 0.71, 0.94; respectively).
Among premenopausal women, greater adolescent
somatotype (OR per 1-unit increase = 0.90; 95 % CI:
0.82, 0.99), BMI at age 18 (OR per 5-unit increase = 0.80;
95 % CI: 0.65, 0.97), birth index (OR per 102-unit in-
crease [which represents a comparison of a woman with
four births at ages at 20, 23, 26, and 29 to a nulliparous
woman] = 0.66; 95 % CI: 0.43,1.01), and age at menarche
(OR per 2-year increase = 0.85; 95 % CI: 0.74, 0.98) were
inversely associated with breast cancer risk (Table 2).
While age at menarche was not mediated by percent
MD, both adolescent somatotype and BMI at age 18
were mediated by percent MD (percent mediated = 73 %
and 82 %, p = 0.05 and 0.04 respectively). Though not
statistically significant at the 5 % level, there was some
evidence that both dense area and non-dense area
mediated the associations with adolescent body size
(percent mediated = 22 %, p = 0.09 for dense area and
percent mediated = 35 %, p = 0.11 for non-dense area)
and BMI at age 18 (percent mediated = 18 %, p = 0.10
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for dense area and percent mediated = 40 %, p = 0.11
for non-dense area). When we adjusted for current
BMI in a sensitivity analysis, the percent mediated by
percent MD for adolescent somatotype and BMI at
age 18 was lower (percent mediated = 35 % and 24 %,
p = 0.08 and 0.08 respectively). While not statistically
significant, there was some evidence that the association
between birth index and breast cancer risk in premeno-
pausal women was partially mediated by percent MD
(percent mediated = 38 %, p = 0.08). Among premeno-
pausal women, greater age at first birth (OR per 5-year
increase = 1.18; 95 % CI: 1.03, 1.36), greater height (OR
per 3-inch increase = 1.14; 95 % CI: 1.02, 1.28), family
history of breast cancer (OR = 1.47; 95 % CI: 1.07, 2.01),
and history of biopsy-confirmed BBD (OR = 2.04; 95 %
CI: 1.59, 2.62) were significantly positively associated
with breast cancer risk. History of biopsy-confirmed
BBD was significantly mediated by percent MD (percent












Agea 46.2 (4.6) 46.1 (4.3) 60.1 (7.0) 59.6 (7.4)
Current BMI (kg/m2) 25.2 (4.8) 25.4 (5.1) 25.9 (4.6) 26.1 (5.0)
Childhood somatotype 2.5 (1.2) 2.6 (1.2) 2.2 (1.2) 2.4 (1.3)
Adolescent somatotype 2.8 (1.0) 2.9 (1.1) 2.5 (1.1) 2.7 (1.2)
BMI at age 18 (kg/m2) 20.8 (2.5) 21.1 (2.7) 20.9 (2.4) 21.1 (2.7)
Weight change since 18 (lbs) 26.7 (25.8) 26.3 (25.7) 29.7 (25.4) 29.7 (26.8)
Age at menarche 12.3 (1.4) 12.4 (1.4) 12.5 (1.4) 12.6 (1.4)
Parity (among parous) 2.4 (1.0) 2.5 (1.0) 3.2 (1.5) 3.2 (1.5)
Age at first birth (among parous) 26.3 (4.4) 25.9 (4.1) 25.6 (3.7) 25.2 (3.5)
Breastfeeding (months)
(among parous women who ever breastfed)
16.3 (10.6) 17.1 (11.1) 12.6 (10.8) 11.4 (9.5)
Birth index 46.0 (26.4) 46.7 (25.9) 56.4 (37.4) 55.8 (37.7)
Height (inches) 65.1 (2.6) 64.9 (2.5) 64.5 (2.3) 64.6 (2.4)
Alcohol use (g/day) 4.2 (6.9) 4.2 (6.3) 5.0 (7.5) 4.8 (7.8)
Age at menopause (y) 47.8 (5.8) 46.7 (6.5)
Percent density 46.1 (18.7) 39.7 (19.0) 29.2 (17.6) 24.8 (17.2)
Dense area (cm2) 96.8 (57.5) 81.3 (50.8) 50.7 (38.4) 47.1 (38.9)
Non-dense area (cm2) 121.4 (77.0) 134.4 (80.4) 141.3 (90.3) 157.5 (91.1)
N (percent)
Nulliparous 81 (14.5) 228 (13.2) 65 (8.9) 139 (8.2)
Ever breastfed (among parous) 361 (76.5) 1136 (76.9) 389 (53.6) 940 (55.8)
Personal history of BBD
Confirmed by biopsy 154 (27.5) 287 (16.6) 193 (26.4) 382 (22.5)
Unconfirmed/unknown 170 (30.4) 566 (32.8) 190 (26.0) 423 (25.0)
Family history of breast cancer 67 (12.0) 146 (8.5) 132 (18.1) 225 (13.3)
Hormone therapy usea
Never 191 (26.1) 547 (32.3)
Current 401 (54.9) 789 (46.5)
Past 139 (19.0) 359 (21.2)
Number of individuals missing data on the following variables: breastfeeding (n = 42), birth index (n = 169), alcohol use (n = 275), and age at menopause
(n = 17, postmenopausal only)
BMI body mass index, BBD benign breast disease
aMatching factor (matched at blood collection)
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Table 2 Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for breast cancer risk unadjusted and adjusted for mammographic
density (MD) measures and percent of the association with breast cancer mediated by MD measures in women premenopausal at
mammogram in the NHS/NHSII (N = 559 cases/1727 controls)
Selected risk factor OR (95 % CI)
not adjusted for MD
OR (95 % CI)
adjusted for MD




Percent MDc 0.93 (0.86,1.01) 0.98 (0.90,1.07) 71 % (p = 0.12)
Dense areac 0.93 (0.86,1.01) 0.95 (0.88,1.04) 30 % (p = 0.14)
Non-dense areac 0.93 (0.86,1.01) 0.96 (0.88,1.04) 35 % (p = 0.16)
Adolescent somatotypea
Per 1-unit increase
Percent MDc 0.90 (0.82,0.99) 0.97 (0.88,1.07) 73 % (p = 0.05)
Dense areac 0.90 (0.82,0.99) 0.92 (0.84,1.01) 22 % (p = 0.09)
Non-dense areac 0.90 (0.82,0.99) 0.94 (0.85,1.03) 35 % (p = 0.11)
BMI at age 18 (kg/m2)a
Per 5-unit increase
Percent MDc 0.80 (0.65,0.97) 0.96 (0.78,1.19) 82 % (p = 0.04)
Dense areac 0.80 (0.65,0.97) 0.83 (0.68,1.02) 18 % (p = 0.10)
Non-dense areac 0.80 (0.65,0.97) 0.87 (0.70,1.08) 40 % (p = 0.11)
Weight change since 18b
Per 20-lb increase
Percent MDc 1.03 (0.96,1.12) 1.16 (1.06,1.26) Not mediatedd
Dense areac 1.03 (0.96,1.12) 1.05 (0.97,1.13) Not mediatedd
Non-dense areac 1.03 (0.96,1.12) 1.12 (1.02,1.23) Not mediatedd
BMI (kg/m2)
Per 5-unit increase
Percent MDc 1.03 (0.92,1.16) 1.22 (1.07,1.39) Not mediatedd
Dense areac 1.03 (0.92,1.16) 1.05 (0.93,1.19) Not mediatedd
Non-dense areac 1.03 (0.92,1.16) 1.16 (1.01,1.33) Not mediatedd
Height
Per 3-inch increase
Percent MDc 1.14 (1.01,1.28) 1.14 (1.01,1.29) Not mediatedd
Dense areac 1.14 (1.01,1.28) 1.13 (1.00,1.27) 6 % (p = 0.43)
Non-dense areac 1.14 (1.01,1.28) 1.15 (1.02,1.30) Not mediatedd
Age at menarche
Per 2-year increase
Percent MDc 0.85 (0.74,0.98) 0.83 (0.72,0.96) Not mediatedd
Dense areac 0.85 (0.74,0.98) 0.83 (0.72,0.96) Not mediatedd
Non-dense areac 0.85 (0.74,0.98) 0.84 (0.73,0.97) Not mediatedd
Nulliparous
Nulliparous vs parous
Percent MDc 1.15 (0.86,1.52) 1.07 (0.80,1.42) 52 % (p = 0.35)
Dense areac 1.15 (0.86,1.52) 1.11 (0.84,1.48) 23 % (p = 0.43)
Non-dense areac 1.15 (0.86,1.52) 1.11 (0.84,1.48) 22 % (p = 0.37)
Birth index
Per 102-unit increase
Percent MDc 0.66 (0.43,1.01) 0.77 (0.50,1.19) 38 % (p = 0.08)
Dense areac 0.66 (0.43,1.01) 0.69 (0.45,1.07) 13 % (p = 0.21)
Non-dense areac 0.66 (0.43,1.01) 0.71 (0.46,1.09) 18 % (p = 0.11)
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Table 2 Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for breast cancer risk unadjusted and adjusted for mammographic
density (MD) measures and percent of the association with breast cancer mediated by MD measures in women premenopausal at
mammogram in the NHS/NHSII (N = 559 cases/1727 controls) (Continued)
Parity (among parous)
Per one-child increase
Percent MDc 1.00 (0.90,1.12) 1.03 (0.92,1.16) Not mediatedd
Dense areac 1.00 (0.90,1.12) 1.02 (0.91,1.14) Not mediatedd
Non-dense areac 1.00 (0.90,1.12) 1.01 (0.90,1.13) Not mediatedd
Age at first birth (among parous)
Per 5-year increase
Percent MDc 1.18 (1.03,1.36) 1.18 (1.02,1.36) 3 % (p = 0.58)
Dense areac 1.18 (1.03,1.36) 1.19 (1.03,1.38) Not mediatedd
Non-dense areac 1.18 (1.03,1.36) 1.18 (1.02,1.36) 3 % (p = 0.28)
Breastfeeding (among parous)
Ever vs never
Percent MDc 0.99 (0.76,1.28) 1.00 (0.77,1.30) 89 % (p = 0.92)
Dense areac 0.99 (0.76,1.28) 0.98 (0.75,1.28) Not mediatedd
Non-dense areac 0.99 (0.76,1.28) 1.00 (0.77,1.30) 75 % (p = 0.92)
Breastfeeding (among parous who ever breastfed)
Per 12-month increase
Percent MDc 0.95 (0.81,1.11) 0.93 (0.80,1.08) Not mediatedd
Dense areac 0.95 (0.81,1.11) 0.93 (0.79,1.08) Not mediatedd
Non-dense areac 0.95 (0.82,1.11) 0.95 (0.82,1.11) 1 % (p = 0.92)
Alcohol use
Per 10 g/day increase
Percent MDc 0.98 (0.84,1.15) 0.98 (0.84,1.14) Not mediatedd
Dense areac 0.98 (0.84,1.15) 0.97 (0.83,1.14) Not mediatedd
Non-dense areac 0.98 (0.84,1.15) 0.98 (0.84,1.15) Not mediatedd
Family history of breast cancer
Yes vs no
Percent MDc 1.47 (1.07,2.01) 1.46 (1.06,2.00) 2 % (p = 0.76)
Dense areac 1.47 (1.07,2.01) 1.39 (1.01,1.92) 14 % (p = 0.12)
Non-dense areac 1.47 (1.07,2.01) 1.51 (1.10,2.07) Not mediatedd
History of biopsy-confirmed BBD
Yes vs no
Percent MDc 2.04 (1.59,2.62) 1.81 (1.40,2.32) 17 % (p < 0.01)
Dense areac 2.04 (1.59,2.62) 1.80 (1.40,2.32) 18 % (p < 0.01)
Non-dense areac 2.04 (1.59,2.62) 2.00 (1.56,2.57) 3 % (p = 0.07)
History of unconfirmed BBD
Yes vs no
Percent MDc 1.12 (0.89,1.41) 1.03 (0.82,1.30) 73 % (p = 0.34)
Dense areac 1.12 (0.89,1.41) 1.01 (0.81,1.28) 87 % (p = 0.33)
Non-dense areac 1.12 (0.89,1.41) 1.11 (0.88,1.39) 9 % (p = 0.44)
Adjusted for age (continuous), fasting status (no, yes), time of blood collection (12 am–5:59 am, 6:00 am–7:59 am, 8:00 am–11:59 pm), mammography batch
(NHS batch 1, NHS batch 2, NHSII), current BMI (continuous), BMI at age 18 (continuous), adolescent somatotype (continuous), history of biopsy-confirmed BBD
(no, yes), history of unconfirmed BBD (no, yes), nulliparity (no, yes), parity (continuous), age at first birth (continuous, nulliparous set to median), and age at menarche
(continuous). Percent of the total association (on the log odds scale) between the exposure and breast cancer risk that was mediated by MD was calculated using the
following equation: 1-(lnORadjusted/lnORunadjusted)
BMI body mass index, BBD benign breast disease
aNot adjusted for adolescent somatotype, BMI at age 18, or current BMI
bNot adjusted for current BMI
cSquare-root transformed
dPercent mediated calculated to be <0 %
Bold data in the header of column 2 in order to distinguish column 2 from column 3
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mediated = 17 %, p = <0.01). Dense area significantly me-
diated the association with history of biopsy-confirmed
BBD (percent mediated = 18 %, p < 0.01) whereas non-
dense area did not mediate the association (percent
mediated = 3 %, p = 0.07). The associations between
breast cancer risk and age at first birth, height, and
family history of breast cancer were not mediated by
percent MD (percent mediated <5 %, p ≥ 0.58). Childhood
somatotype, weight change since age 18, current BMI, par-
ity, breastfeeding, alcohol use, and history of unconfirmed
BBD were not significantly associated with breast cancer
risk (p > 0.05) in this subgroup of premenopausal women.
Among postmenopausal women, greater childhood som-
atotype (OR per 1-unit increase = 0.89; 95 % CI: 0.83, 0.96)
and greater adolescent somatotype (OR per 1-unit in-
crease = 0.86; 95 % CI: 0.80, 0.93) were significantly
inversely associated with breast cancer risk (Table 3).
The associations with breast cancer risk for both of
these early life body size measures were significantly
mediated by percent MD (percent mediated = 26 % and
p = 0.01 for both measures). Dense area significantly
mediated the association for both childhood and ado-
lescent somatotype (percent mediated = 16 %, p = 0.02
and percent mediated = 13 %, p = 0.01, respectively).
While there was some evidence that non-dense area
also mediated the association, it was not statistically
significant (percent mediated = 10 %, p = 0.10 and per-
cent mediated = 10 %, p = 0.13, respectively). After ad-
justment for current BMI, both of these associations
were mediated by percent MD, though the percent me-
diated was somewhat lower (percent mediated = 19 %
and 18 %, p = 0.01 and p < 0.01, respectively). Greater
age at first birth, greater months breastfeeding among
those who ever breastfed, family history of breast can-
cer, history of biopsy-confirmed BBD, greater age at
menopause, and current HT use were positively associ-
ated with breast cancer risk (p < 0.05). The association
between history of biopsy-confirmed BBD and breast
cancer risk was mediated by percent MD (percent
mediated = 33 %, p = 0.04). There was some evidence
that dense area mediated the association with BBD
(percent mediated = 24 %, p = 0.05), but less evidence for
non-dense area (percent mediated = 8 %, p = 0.12). In
addition, percent MD significantly mediated the associ-
ation with breast cancer risk for current HT use (percent
mediated = 22 %, p < 0.01). Further, both dense area and
non-dense area mediated the association with current HT
use (percent mediated = 14 %, p < 0.01 and percent medi-
ated = 7 %, p = 0.02, respectively). In addition, there was
some evidence that the association with greater age at first
birth was partially mediated by percent MD (percent
mediated = 13 %, p = 0.05). The associations between
breast cancer risk and greater months breastfeeding
among those who ever breastfed, family history of breast
cancer, and greater age at menopause were not signifi-
cantly mediated by percent MD (percent mediated ≤5 %,
p ≥ 0.22). Current BMI, BMI at age 18, weight change
since age 18, age at menarche, parity, birth index,
breastfeeding (ever/never), height, alcohol use, history
of unconfirmed BBD, and past HT use were not signifi-
cantly associated with breast cancer risk in this sample
of postmenopausal women. In secondary analyses, we
observed little evidence of interaction between the
selected risk factors and percent MD on breast cancer
risk. Significant interaction (p ≤ 0.05) was only observed
for birth index, breastfeeding among women who ever
breastfed, and height (Additional file 3: Table S3 and
Additional file 4: Table S4). Modeling interaction between
the exposures and percent MD produced similar results to
our primary analysis, though the estimates of percent
mediated in premenopausal women did vary by the level
of percent MD in the referent category for birth index
(Additional file 3: Table S3). In this secondary analysis,
a substantial portion of the effect of adolescent somato-
type and of BMI at age 18 among premenopausal
women was mediated by percent MD and suggests that
this mediation was robust to potential unmeasured
confounding by common causes of percent MD and
breast cancer. To completely account for the mediated
effect for adolescent somatotype among premenopausal
women, an unmeasured confounder that increased per-
cent MD by two-thirds of a standard deviation would
have to increase breast cancer risk by at least 2.1-fold.
To completely account for the mediated effect for
BMI at age 18 among premenopausal women, an un-
measured confounder that increased percent MD by
two-thirds of a standard deviation would have to in-
crease risk by at least 2.8-fold. Substantial unmeasured
confounding would thus be required to completely
explain away these mediated effects of adolescent
somatotype and of BMI at age 18 among premeno-
pausal women.
Discussion
Among premenopausal women, we observed that per-
cent MD significantly mediated the associations of
adolescent somatotype and BMI at age 18 with breast
cancer risk. In postmenopausal women, associations of
early life body size measures with breast cancer risk,
specifically childhood and adolescent somatotype, were
also significantly mediated by percent MD, though the
percent mediated was more modest than in premeno-
pausal women. Further, the association between current
HT use and breast cancer risk was also significantly medi-
ated by percent MD in postmenopausal women. The asso-
ciations between personal history of biopsy-confirmed
BBD and breast cancer risk were significantly mediated by
percent MD in both pre- and postmenopausal women.
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Table 3 Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for breast cancer risk unadjusted and adjusted for mammographic
density (MD) measures and percent of the association with breast cancer mediated by MD measures in women postmenopausal at
mammogram in the NHS/NHSII (N = 731 cases/1695 controls)
Selected risk factor OR (95 % CI)
not adjusted for MD
OR (95 % CI)
adjusted for MD




Percent MDc 0.89 (0.83,0.96) 0.92 (0.85,0.99) 26 % (p = 0.01)
Dense areac 0.89 (0.83,0.96) 0.91 (0.84,0.98) 16 % (p = 0.02)
Non-dense areac 0.89 (0.83,0.96) 0.90 (0.84,0.97) 10 % (p = 0.10)
Adolescent somatotypea
Per 1-unit increase
Percent MDc 0.86 (0.80,0.93) 0.90 (0.83,0.97) 26 % (p = 0.01)
Dense areac 0.86 (0.80,0.93) 0.88 (0.81,0.95) 13 % (p = 0.01)
Non-dense areac 0.86 (0.80,0.93) 0.88 (0.81,0.95) 10 % (p = 0.13)
BMI at age 18 (kg/m2)a
Per 5-unit increase
Percent MDc 0.88 (0.74,1.05) 1.00 (0.83,1.19) 98 % (p = 0.17)
Dense areac 0.88 (0.74,1.05) 0.92 (0.77,1.10) 35 % (p = 0.19)
Non-dense areac 0.88 (0.74,1.05) 0.94 (0.78,1.13) 51 % (p = 0.24)
Weight change since 18b
Per 20-lb increase
Percent MDc 1.03 (0.96,1.10) 1.11 (1.03,1.19) Not mediatedd
Dense areac 1.03 (0.96,1.10) 1.04 (0.97,1.12) Not mediatedd
Non-dense areac 1.03 (0.96,1.10) 1.10 (1.01,1.19) Not mediatedd
BMI (kg/m2)
Per 5-unit increase
Percent MDc 1.05 (0.95,1.16) 1.17 (1.05,1.30) Not mediatedd
Dense areac 1.05 (0.95,1.16) 1.07 (0.96,1.18) Not mediatedd
Non-dense areac 1.05 (0.95,1.16) 1.16 (1.02,1.30) Not mediatedd
Height
Per 3-inch increase
Percent MDc 0.95 (0.85,1.06) 0.96 (0.86,1.07) 22 % (p = 0.41)
Dense areac 0.95 (0.85,1.06) 0.95 (0.85,1.06) Not mediatedd
Non-dense areac 0.95 (0.85,1.06) 0.96 (0.86,1.07) 20 % (p = 0.39)
Age at menarche
Per 2-year increase
Percent MDc 0.92 (0.80,1.05) 0.93 (0.81,1.06) 11 % (p = 0.37)
Dense areac 0.92 (0.80,1.05) 0.93 (0.81,1.06) 13 % (p = 0.31)
Non-dense areac 0.92 (0.80,1.05) 0.92 (0.80,1.05) Not mediatedd
Nulliparous
Nulliparous vs parous
Percent MDc 1.22 (0.88,1.69) 1.12 (0.80,1.56) 43 % (p = 0.26)
Dense areac 1.22 (0.88,1.69) 1.14 (0.82,1.59) 32 % (p = 0.28)
Non-dense areac 1.22 (0.88,1.69) 1.19 (0.86,1.65) 11 % (p = 0.36)
Birth index
Per 102-unit increase
Percent MDc 0.96 (0.73,1.25) 1.04 (0.79,1.36) Not mediatede
Dense areac 0.96 (0.73,1.25) 1.01 (0.78,1.33) Not mediatede
Non-dense areac 0.96 (0.73,1.25) 0.97 (0.74,1.27) 38 % (p = 0.75)
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Table 3 Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for breast cancer risk unadjusted and adjusted for mammographic
density (MD) measures and percent of the association with breast cancer mediated by MD measures in women postmenopausal at
mammogram in the NHS/NHSII (N = 731 cases/1695 controls) (Continued)
Parity (among parous)
Per one-child increase
Percent MDc 1.02 (0.95,1.09) 1.03 (0.96,1.11) Not mediatedd
Dense areac 1.02 (0.95,1.09) 1.03 (0.96,1.10) Not mediatedd
Non-dense areac 1.02 (0.95,1.09) 1.02 (0.95,1.09) Not mediatedd
Age at first birth (among parous)
Per 5-year increase
Percent MDc 1.23 (1.07,1.41) 1.19 (1.04,1.38) 13 % (p = 0.05)
Dense areac 1.23 (1.07,1.41) 1.20 (1.05,1.39) 9 % (p = 0.09)
Non-dense areac 1.23 (1.07,1.41) 1.21 (1.05,1.40) 5 % (p = 0.15)
Breastfeeding (among parous)
Ever vs never
Percent MDc 0.96 (0.79,1.16) 0.97 (0.80,1.17) 22 % (p = 0.70)
Dense areac 0.96 (0.79,1.16) 0.96 (0.79,1.17) 11 % (p = 0.74)
Non-dense areac 0.96 (0.79,1.16) 0.97 (0.80,1.17) 19 % (p = 0.68)
Breastfeeding (among parous women who ever breastfed)
Per 12-month increase
Percent MDc 1.25 (1.06,1.46) 1.25 (1.06,1.47) Not mediatedd
Dense areac 1.25 (1.06,1.46) 1.24 (1.06,1.46) 2 % (p = 0.57)
Non-dense areac 1.25 (1.06,1.46) 1.26 (1.07,1.48) Not mediatedd
Alcohol use
Per 10 g/day increase
Percent MDc 1.01 (0.90,1.14) 1.00 (0.89,1.13) 73 % (p = 0.85)
Dense areac 1.01 (0.90,1.14) 1.01 (0.90,1.13) 41 % (p = 0.85)
Non-dense areac 1.01 (0.90,1.14) 1.01 (0.90,1.13) 38 % (p = 0.85)
Family history of breast cancer
Yes vs no
Percent MDc 1.45 (1.15,1.85) 1.45 (1.14,1.84) 1 % (p = 0.78)
Dense areac 1.45 (1.15,1.85) 1.44 (1.14,1.84) 2 % (p = 0.52)
Non-dense areac 1.45 (1.15,1.85) 1.46 (1.15,1.86) Not mediatedd
History of biopsy-confirmed BBD
Yes vs no
Percent MDc 1.29 (1.04,1.61) 1.19 (0.95,1.48) 33 % (p = 0.04)
Dense areac 1.29 (1.04,1.61) 1.22 (0.98,1.52) 24 % (p = 0.05)
Non-dense areac 1.29 (1.04,1.61) 1.27 (1.02,1.58) 8 % (p = 0.12)
History of unconfirmed BBD
Yes vs no
Percent MDc 1.19 (0.95,1.48) 1.13 (0.90,1.41) 29 % (p = 0.17)
Dense areac 1.19 (0.95,1.48) 1.13 (0.91,1.41) 28 % (p = 0.17)
Non-dense areac 1.19 (0.95,1.48) 1.19 (0.95,1.48) 0 % (p = 0.97)
Age at menopause
Per 4-year increase
Percent MDc 1.12 (1.05,1.20) 1.12 (1.04,1.19) 5 % (p = 0.22)
Dense areac 1.12 (1.05,1.20) 1.12 (1.05,1.20) 3 % (p = 0.30)
Non-dense areac 1.12 (1.05,1.20) 1.12 (1.05,1.20) 3 % (p = 0.20)
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The associations of other risk factors, such as age at me-
narche, age at first birth, height, family history of breast
cancer, and age at menopause with breast cancer risk were
not mediated by percent MD.
Several prior studies have observed that greater body
fatness in childhood and adolescence is associated with
lower risk of breast cancer in adulthood [23–28] as well
as lower percent MD in adulthood [6, 10, 29–34]. Some
studies have examined whether the association between
early life body size and breast cancer risk is mediated by
MD, however none have attempted to quantify the ex-
tent to which the associations are mediated by MD. In a
prior study in the NHS/NHSII, the associations between
childhood somatotype, adolescent somatotype, and BMI
at age 18 and breast cancer risk were partially attenuated
when models were adjusted for percent MD, consistent
with our current study [10]. In addition, a study of over
13,000 women 50 years of age or older in Denmark
observed that childhood BMI was inversely associated
with risk of breast cancer [33]. When adjusted for a
binary classification of MD (fatty breasts vs mixed/dense
breasts), these associations were attenuated. For example,
the hazard ratio (HR) for the association between the
BMI at age 7 (per z-score) and breast cancer risk was
0.91 (95 % CI: 0.83–0.99) in age and birth cohort
adjusted models, whereas the HR was 0.97 (95 % CI:
0.88–1.06) after further adjusting for MD. However,
this study had several limitations including a binary
classification of MD as well as limited ability to adjust
for potential confounders. While prior studies have ob-
served that history of BBD and percent MD are independ-
ent risk factors for breast cancer [35], to our knowledge
no studies have examined the extent to which the associ-
ation between BBD and breast cancer is mediated by MD.
In the current study, we observed that the association be-
tween biopsy-confirmed BBD and breast cancer risk was
attenuated after adjustment for percent MD. However,
while we used information on BBD diagnosis prior to the
mammogram date, it is likely that women with BBD had
higher percent MD at the time of the biopsy compared to
women without BBD. Further, some studies suggest that
high percent MD may lead to the development of incident
BBD [36]. Therefore, percent MD is unlikely be a down-
stream consequence of BBD, but rather a co-morbidity of,
or a risk factor for, BBD [35, 36]. Previous research has
observed that HT use is associated with greater percent
MD [37, 38] as well as an increased risk of breast cancer
[39]. In an analysis of over 1700 postmenopausal women
from three case-control studies, current hormone therapy
use was associated with an increased risk of breast cancer
(OR = 1.26, 95 % CI: 1.00–1.59), which was partially atten-
uated after adjustment for percent MD (OR = 1.19, 95 %
CI: 0.94–1.51) [11]. Interestingly, this attenuation of 25 %
is very similar to our observation that the percent medi-
ated for association with current HT use was 22 %.
Our study has several limitations. The associations
between exposures and risk, as well as the proportion
of the associations that are mediated by MD, may differ
Table 3 Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for breast cancer risk unadjusted and adjusted for mammographic
density (MD) measures and percent of the association with breast cancer mediated by MD measures in women postmenopausal at
mammogram in the NHS/NHSII (N = 731 cases/1695 controls) (Continued)
Hormone therapy use
Past vs never
Percent MDc 1.18 (0.91,1.53) 1.12 (0.86,1.46) 31 % (p = 0.26)
Dense areac 1.18 (0.91,1.53) 1.15 (0.88,1.50) 14 % (p = 0.31)
Non-dense areac 1.18 (0.91,1.53) 1.15 (0.88,1.50) 13 % (p = 0.31)
Hormone therapy use
Current vs never
Percent MDc 1.71 (1.37,2.13) 1.52 (1.22,1.90) 22 % (p < 0.01)
Dense areac 1.71 (1.37,2.13) 1.58 (1.27,1.98) 14 % (p < 0.01)
Non-dense areac 1.71 (1.37,2.13) 1.65 (1.32,2.05) 7 % (p = 0.02)
Adjusted for age (continuous), fasting status (no, yes), time of blood collection (12 am–5:59 am, 6:00 am–7:59 am, 8:00 am–11:59 pm), mammography batch (NHS
batch 1, NHS batch 2, NHSII), current BMI (continuous), BMI at age 18 (continuous), adolescent somatotype (continuous), history of biopsy-confirmed BBD (no, yes),
history of unconfirmed BBD (no, yes), nulliparity (no, yes), parity (continuous), age at first birth (continuous, nulliparous set to median), age at menarche (continuous),
and HT use (never, past, current). Percent of the total association (on the log odds scale) between the exposure and breast cancer risk that was mediated by MD was
calculated using the following equation: 1-(lnORadjusted/lnORunadjusted)
BMI body mass index, BBD benign breast disease
aNot adjusted for adolescent somatotype, BMI at age 18, or current BMI
bNot adjusted for current BMI
cSquare-root transformed
dPercent mediated calculated to be <0 %
ePercent mediated calculated to be >100 %
Bold data in the header of column 2 in order to distinguish column 2 from column 3
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by breast cancer subtype (e.g., ER status). However, we
had insufficient power in this analysis to examine the
proportion mediated by MD according to breast cancer
subtype. Further, we were unable to further stratify by
menopausal status at diagnosis due to limited power
and were able to measure MD at only one point in
time. All exposure data is self-reported, which may re-
sult in some misclassification. However, data on all ex-
posures was collected prior to both the mammogram
and breast cancer diagnosis, therefore any misclassifica-
tion should be non-differential with respect to both
MD measurements and case-control status. While MD
measures are highly reproducible, there is the possibility
for random error. As the mammogram reader was blinded
to both exposure and case-control status, any misclassifi-
cation of MD should be non-differential. Non-differential
measurement error in the mediator tends to bias the
mediated effects toward the null so the true proportion
mediated measures may in fact be larger than those re-
ported here [22, 40]. Due to the limitations of our data,
the effect estimates between risk factors and breast cancer
risk should be interpreted as associations and our esti-
mates of mediation by percent MD should be interpreted
as statistical mediation and not necessarily causal. How-
ever, the results for the mediated effect for adolescent
somatotype and for BMI at age 18 among premenopausal
women seemed robust to potential unmeasured con-
founding of MD and breast cancer risk. The NHS/NHSII
may have different distributions of risk factors compared
to other US populations (e.g., women in the NHS were
married at enrollment and were more likely to be parous).
Therefore, confirmation of these results in other cohorts
is warranted. The strengths of our study include the cen-
tralized collection and reading of mammograms, the first
quantitative assessment of mediation by MD on breast
cancer risk, and detailed adjustment for potential con-
founders of the relationships between the exposure and
mediator, the exposure and outcome, and the mediator
and outcome.
Conclusions
Overall, we observed that percent MD partially medi-
ated some of the associations between established
breast cancer risk factors and breast cancer risk, though
the magnitude varied by risk factor and menopausal
status. In particular, early life body size was significantly
mediated in both pre- and postmenopausal women as
was HT use in postmenopausal women. This work sug-
gests that the utility of percent MD as an intermediate
marker of breast cancer risk may depend on the exposure
under study. Additional research is necessary to confirm
these observations as well as to explore whether the extent
to which MD mediates the associations with established
breast cancer risk factors varies by breast cancer subtype.
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